French govt launches Rx tax for medicines R&D
France's President Nicolas Sarkozy has announced the creation of a "medical franchise" of 0.50 euros ($0.68) per drug package to fund research into cancer, Alzheimer's disease and palliative care. The news came during a presidential visit to a care home and an AD treatment center in the south western city of Dax, France. Pres Sarkozy was accompanied by the Health Minister, Roselyne Bachelot.
The proposed surcharge would not be levied on drugs prescribed for children, pregnant women or very low-income households, the President's office confirmed.
Pres Sarkozy also announced that Joel Menard, a professor of medicine, has been asked to chair a commission that is due to develop an AD plan to be launched by the end of the year. The President said that Prof Menard "must assemble the best experts and present his proposals on September 21," to coincide with the global day of action against AD.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze